Dutasteride add-on therapy reduces detrusor mass in patients with benign prostatic enlargement not satisfied with alpha-adrenergic antagonist monotherapy: A single center prospective study.

Cosimo De Nunzio Aldo BrassettiFlavia ProiettiMauro GacciSergio SerniFrancesco EspertoAndrea Tubaro

Published in: Neurourology and urodynamics (2017)

Dutasteride add-on therapy significantly reduced IPP and detrusor mass and was effective in improving LUTS in patients with BPE not satisfied with αBs monotherapy. The possible role of BWT and IPP as proxies of medical treatment outcomes should be confirmed by further studies.

Keyphrases

benign prostatic hyperplasia
lower urinary tract symptoms
combination therapy
open label
prostate cancer
randomized controlled trial
clinical trial
cell therapy
mesenchymal stem cells
smoking cessation
chemotherapy induced